pharmaphorum

ESMO25: On next-generation bispecifics, with Tadaaki Taniguchi

At ESMO 2025 in Berlin, pharmaphorum spoke with Tadaaki Taniguchi, Chief Research & Development Officer at Astellas, about ...
pharmaphorum

Update: MSD's $9.2bn deal for flu biotech Cidara confirmed

MSD has announced a takeover deal for Cidara Therapeutics, an infectious disease specialist currently focused on developing a ...
pharmaphorum

Lundbeck makes bid for Avadel, trying to displace Alkermes

In a statement, Avadel acknowledged that it had received the Lundbeck bid and that its board of directors had "determined in ...
pharmaphorum

Kura scores FDA okay for rival to Syndax's leukaemia drug

Kura Oncology has claimed FDA approval for oral menin inhibitor Komzifti for a form of acute myeloid leukaemia (AML), making ...
pharmaphorum

Sanofi's type 1 diabetes drug poised for EU rollout

On World Diabetes Day, Sanofi is celebrating an approval recommendation in the EU for Teizeild, a first-in-class drug ...
pharmaphorum

World Diabetes Day: Type 1 diabetes in the spotlight and under the microscope

This World Diabetes Day, Sanofi UK and DigiBete are hosting a pop-up event in Leeds today and tomorrow, 14th & 15th November, ...
pharmaphorum

Medicxi raises €500m for latest biotech fund

Anglo-Swiss life sciences investment company Medicxi has raised €500 million (around $579 million) for its sixth fund, which will focus on supporting 'asset-centric' companies at all stages of drug ...